What does “extended genotyping” mean in the context of HPV testing?
HPV assays with partial
genotyping
Report multiple high-risk HPV (hr-HPV) genotypes in a single, pooled result1
BD OnclarityTM HPV Assay
with extended genotyping
Reports 6 hr-HPV genotypes individually and the other 8 hr-HPV genotypes in strategic, small groups1,2
May mask the true risk of CIN3+ disease due to HPV 31 and will likely lead to a one-year follow-up recommendation instead of an immediate colposcopy referral3–5
Can individually identify HPV 31, which poses a similar risk for cervical precancer and cancer as compared to HPV 184
Prohibits monitoring of genotype-specific HPV persistence beyond HPV 16 and 184
Can track genotype-specific hr-HPV persistence, the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype4,6–8
Extended genotyping allows for a more precise way to measure your patient’s risk for developing cervical precancer and cancer vs. a pooled, high-risk assay.3,9
Learn more about extended genotyping with the BD Onclarity™ HPV Assay
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hr, high risk
1. Salazar K et al. J Am Soc Cytopath. 2019;8:284–92.
2. BD OnclarityTM HPV Assay US Package Insert [8089894].
3. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102–31.
4. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13.
5. Stoler MH et al. Am J Clin Pathol. 2019;151(4):433–42.
6. Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
7. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–72.
8. Bodily J, Laimins LA. Trends Microbiol. 2011;19(1):33–9.
9. Demarco M et al. E Clinical Medicine 22. 2020;100293.